This is a preview of subscription content, log in via an institution to check access.
Notes
including pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
Reference
Saudi Food and Drug Authority (SFDA). Switching between Warfarin Brands and The Importance of Close Monitoring of INR. Internet Document : [2 pages], 9 Jun 2020. Available from: URL: https://www.sfda.gov.sa/ar/drug/about/sector_departments/national_pharmacovigilance_center/Documents/D-SwitchingWarfarinBrands-ImportanceCloseMonitoring-INR.pdf
Rights and permissions
About this article
Cite this article
SFDA: importance of INR monitoring when switching warfarin brands. Reactions Weekly 1810, 4 (2020). https://doi.org/10.1007/s40278-020-80024-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-80024-6